Navigation Links
OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
Date:9/22/2010

be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, uncertainties regarding our future operating results, the risk that our product candidates will not obtain the requisite regulatory approvals to commercialize or that the future sales of our product candidates may be less than expected, and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2009 and the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Reports Second Quarter Financial Results
2. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
6. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
7. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
8. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
9. OncoGenex Reports Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Mass. , April 16, 2015  In recognition of ... collaborated with hemophilia advocacy groups to illuminate more than 15 ... , including Boston,s Zakim Bridge and ... New Orleans, Mercedes-Benz Superdome and ... occur during the evening of April 17, and coincide with ...
(Date:4/16/2015)... /CNW/ - Bioenterprise Corporation is pleased to announce that it ... Charlottetown , PEI.  Bioenterprise has established a 3-year ... for the commercialization of agricultural technologies and innovations. ... ADAPT.  They have been at the heart of agri-innovation ... Dave Smardon , President & CEO of Bioenterprise ...
(Date:4/16/2015)... April 16, 2015  AnaptysBio, Inc., a leader ... antibodies, today announced the advancement of its ... IND-enabling studies. The Company,s anti-IL-36R therapeutic antibody, ... generalized pustular psoriasis (GPP), an orphan systemic ... is wholly owned within AnaptysBio,s proprietary antibody ...
(Date:4/16/2015)... , April 16, 2015  EMD Serono today ... Darmstadt, Germany , appointed ... Head of Global Clinical Development.  Dr. Reicin brings ... experience in Oncology and Immunology. She is an ... served as a Vice President in various capacities ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3
... the only one completely confused by the Cingular merger with ... facts of the deal. Cingular Wireless acquires the assets and ... have 46 million customers, topping now No. 2 carrier Verizon ... keeps the rights to the AT&T Wireless brand and plans ...
... of the statewide Wisconsin business-plan contest this year ... survive the first round than they did during the inaugural ... initial abstracts of business ideas has passed, a panel of ... The survivors, who must write extended summaries for a further ...
... of Wisconsin-Milwaukee The director of the university's ... would leave for the University of Cincinnati in April. Professor ... feel valued, and that UW-Milwaukee does not have good ... , Menasha, Wis. Banta Corporation said it would ...
Cached Biology Technology:Cingular confusion 2Cingular confusion 3Coaching available for business-plan contest survivors 2
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... - The idea is to teach the immune system of ... attack the insulin-producing cells of the pancreas. "We want ... who directs the Medical College of Georgia Immunotherapy Center. Type ... immune system targets healthy islet cells for destruction, leaving young ...
... , CAREFREE, A.Z. - Data from the ELLA ... time at the American Association for Cancer Research Conference on ... "Hispanics are the fastest-growing minority group in the United ... cancer," said Elena Martinez, Ph.D., professor of epidemiology at The ...
... a 60-million-year-old South American snake whose length and weight ... bit cuter and more cuddly. Named Titanoboa ... snake,s vertebrae suggest it weighed 1,140 kilograms (2,500 pounds) ... tip -- and that,s a conservative estimate. A report ...
Cached Biology News:Molecule that suppresses immune response under study in type 1 diabetes 2Molecule that suppresses immune response under study in type 1 diabetes 3Hispanic women and breast cancer: An understudied group 2Hispanic women and breast cancer: An understudied group 3Hispanic women and breast cancer: An understudied group 4At 2,500 pounds and 43 feet, prehistoric snake is the largest on record 2At 2,500 pounds and 43 feet, prehistoric snake is the largest on record 3
... Detergent Clean-up Micro Kit provides a fast and ... Triton X-100 and other detergents from small samples ... Norgens patented protein resin as an ion exchanger. ... g of either acidic or basic protein.A complete ...
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... cells form from a hematopoietic stem cells ... to the bone surface and lowering the ... around 4.5. The bone mineral is then ... and function is controlled primarily by Macrophage ...
Values of steady state parameters for enzyme activities are determined....
Biology Products: